Is it a blessing or a curse that the number of new drug approvals dropped sharply in 2013?

Source: medical geography January 15, 2014, the wave of new drug approval established by the US FDA has now been broken According to official statistics, only 27 new drugs were approved in the biopharmaceutical industry in 2013, down sharply from 39 in 2012 People began to question the productivity and sustainability of R & D projects in the global pharmaceutical industry In 2012, some experts in the United States boasted that the industry has entered a new era of development, and now the speed and quantity of new drug approval in the United States has surpassed that in Europe However, in terms of 2013 data, compared with the average 35 new drugs per year predicted by McKinsey consulting company from 2000 to 2016, the average 24 approvals per year today is a little bleak The main reason for the sudden drop in the number of new drug approvals in the above-mentioned years is the sharp drop in the number of new drug applications, although the FDA has launched a "breakthrough therapy identification" that can accelerate the drug development and approval process Unfortunately, the FDA's "breakthrough therapy certification" did not significantly increase the number of new drug approvals Even large pharmaceutical companies like Lilly have failed in clinical research projects Innovative biotech companies like biogenidec and Gilead have benefited from exclusive new potential therapies The bosses of some large pharmaceutical companies are also busy adjusting the layout Johnson & Johnson is working with pharmaceuticals to gain more market share in the blood cancer drug imbruvica While Roche continues the tradition and continues to develop new anti-tumor therapy, kadcyla and gazyva are the representatives Deep level innovation problems are perplexing other big pharmaceutical companies, such as GlaxoSmithKline, with a series of new licensing in 2013, indicating that the restructuring four years ago has begun to work However, in late 2013, the company's new drug development suffered a series of setbacks and failures, such as the development of new cancer vaccine, DMD therapy and heart disease drug darapladib And Lilly is a year of no results, and MSD has given up the long-term adherence to drug innovation From the FDA's point of view, when the number of new drug approvals in 2012 reached the peak since 1997, many projects need to be operated at the same time, which seems to be in a hurry Now, it's good for their jobs to have 32 applications In the past few years, the contribution of large pharmaceutical companies to new drug approval has remained stable Bernard munos of innothink said: "2012 will be the peak year of new drug approval, which can be attributed to the surge of approval of small pharmaceutical enterprises." "The industry seems to be getting better, but it is still facing challenges," Munos added "At present, the most worrying are two trends: declining sales peaks and extreme product prices